A Phase 3 interventional study of Bomedemstat and Anagrelide in Essential Thrombocythemia, sponsored by Merck Sharp & Dohme LLC. Active, not recruiting at 161 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Thrombocythemia, Essential with a site in China — 6 open to participants now, 10 under way, 3 of them phase 3. Thrombocythemia, Essential · China.
Among the 11 studies in Thrombocythemia, Essential with a site in China, this one is the only one that started in 2023, is one of 3 in phase 3, and was the 7th registered.
229 studies on the registry are indexed under Thrombocythemia, Essential; 38 are open to participants now.
Browse Thrombocythemia, Essential studies →6 of the 11 studies in Thrombocythemia, Essential with a site in China are open now. Recruiting first, the newest first:
Zhenya Hong · Sites in China
Ages 18+
Xiamen Amoytop Biotech Co., Ltd. · Sites in China
Ages 18+
Hangzhou GluBio Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Nanfang Hospital, Southern Medical University · Sites in China
Ages 18–64
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 34 Thrombocythemia, Essential studies recruiting now, 30 (88%) set no upper age limit and 3 (9%) stop at 75 or younger; 5 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 340 is above the median of 52 across 168 interventional studies indexed under Thrombocythemia, Essential.
Median enrollment 124 across the 8 interventional studies, 120 across the 3 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
6 of 11 have an industry lead sponsor. The 9 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 5 studies filed under Thrombocythemia, Essential — fewer than ten, so there is no comparison to draw.
5 of the studies in Thrombocythemia, Essential with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06079879Phase 3Merck Sharp & Dohme LLCA Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) | 2027-07-14 |
| NCT06456346Phase 3Merck Sharp & Dohme LLCBomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) | 2027-09-28 |
| NCT06734637Zhenya HongEfficacy and Safety of Peginterferon in ET and PV. | 2026-11-20 |
| NCT06378437Hangzhou GluBio Pharmaceutical Co., Ltd.A Study of GLB-001 in Patients With Myeloid Malignancies | 2026-12-31 |
| NCT04279847Incyte CorporationSafety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms | 2027-04-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 11 studies in Thrombocythemia, Essential with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate response to or are intolerant of hydroxyurea. The primary study hypothesis is that bomedemstat is superior to the best available therapy with respect to durable clinicohematologic response (DCHR).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will begin treatment at a dose of 50 mg of bomedemstat daily. Dosage will be adjusted either up or down within specified time parameters for each participant to the dose that provides sufficient exposure to safely inhibit thrombopoiesis to decrease platelet counts to the target range. All participants will be treated daily for up to 52 weeks and are eligible for an extended treatment phase up to an additional 156 weeks.
Drug: Bomedemstat
Each participant will receive either anagrelide, busulfan, interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b, or ruxolitinib as determined by investigator. All participants will be treated per respective approved product labels for up to 52 weeks. Participants receiving BAT for 52 weeks who stop responding to BAT are eligible to switch to bomedemstat and receive this for up to 156 weeks at the investigator's discretion.
Drug: Anagrelide · Drug: Busulfan · Drug: Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b · Drug: Ruxolitinib
Oral Capsule
Also known as: MK-3543, IMG-7289, Bomedemstat tosylate
Oral Capsule
Oral Tablet
Drug pages: Interferon Alpha · Interferon alpha-2
Subcutaneous Solution
Oral Tablet
Durable Clinicohematologic Response (DCHR) Rate
DCHR rate is the percentage of participants with DCHR, defined as a confirmed reduction of platelet count to ≤400 × 10\^9/L and absence of white blood cell (WBC) count elevation to \>10 × 10\^9/L locally assessed to be due to ET, starting by Week 24 and maintained for at least 24 weeks, and the absence of any thrombotic or major hemorrhagic events or disease progression to myelofibrosis (MF), myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) by Week 52.
Time frame: Up to approximately 52 weeks
Clinicohematologic Response (CHR) Rate
CHR rate is the percentage of participants with CHR, defined as a confirmed reduction of platelet count to ≤400 × 10\^9/L and absence of WBC count elevation to \>10 × 10\^9/L locally assessed to be due to ET, maintained for at least 12 weeks, and the absence of any thrombotic or major hemorrhagic events or disease progression to MF, MDS or AML by Week 52.
Time frame: Up to approximately 52 weeks
Hematologic Response (HR) Rate
HR rate is the percentage of participants with HR, HR is defined as the time from the first confirmed hematologic response to first documented evidence of confirmed platelet increase or confirmed WBC increase after latest confirmed hematologic response date.
Time frame: Up to approximately 52 weeks
Change From Baseline in Patient-reported Outcomes Measurement Information System (PROMIS) Fatigue SF-7a Total Fatigue Score
The PROMIS Fatigue SF-7a is a 7-item participant-reported assessment that measures both the experience of fatigue and the interference of fatigue on daily activities over the past week. Response options are on a 5-point Likert scale, ranging from 1 = never to 5 = always. The total score is used in the analysis and is obtained by summing keyed scores of all items. Scores can range from 7 to 35, with higher scores indicating greater fatigue.
Time frame: Baseline and pre-specified timepoints through Week 52
Change From Baseline in Total Symptom Score as Measured on the MFSAF v4.0
The MFSAF v4.0 is a 7-item participant-reported myelofibrosis symptom assessment which asks respondents to report symptom severity at its worst for each of the 7 items on a 0 (Absent) to 10 (Worst Imaginable) numeric rating scale.
Time frame: Baseline and pre-specified timepoints through Week 52
Duration of Durable Clinicohematologic Response (DODCHR)
For participants who demonstrate DCHR, DODCHR is defined as the time from the first documented evidence of confirmed reduction of platelet and WBC counts until confirmed increase of platelet and WBC counts to above acceptable threshold, thrombotic or major hemorrhagic events, or disease progression to MF, MDS or AML.
Time frame: Up to approximately 52 weeks
Duration of Clinicohematologic Response (DOCHR)
For participants who demonstrate CHR, DOCHR is defined as the time from the first documented evidence of confirmed reduction of platelet and WBC counts until confirmed increase of platelet and WBC count to above acceptable threshold, thrombotic or major hemorrhagic events, or disease progression to MF, MDS or AML.
Time frame: Up to approximately 52 weeks
Duration of Hematologic Response (DOHR)
For participants who demonstrate HR, DOHR is defined as the time from the first confirmed hematologic response to first documented evidence of confirmed platelet increase or confirmed WBC increase after latest confirmed hematologic response date.
Time frame: Up to approximately 52 weeks
Percentage of Participants with Thrombotic Events
Thrombotic events include but are not limited to new or recurrent acute myocardial infarction, unstable angina, stroke, transient ischemic attack, deep venous thrombosis, pulmonary embolism, thrombotic digital ischemia, or other thrombotic events.
Time frame: Up to approximately 52 weeks
Percentage of Participants with Major Hemorrhagic Events
Major hemorrhagic events include but are not limited to fatal bleeding, and/or symptomatic bleeding in a critical area or organ such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a decrease in hemoglobin level of 2 g/dL or more, or leading to transfusion of 2 or more units of whole blood or red cells.
Time frame: Up to approximately 52 weeks
Percentage of Participants with Disease Progression to Post-ET MF or MDS/AML
Disease progression rate is the percentage of participants with disease progression, defined as the transformation to post-ET MF, MDS, or AML as assessed by the adjudication committee.
Time frame: Up to approximately 52 weeks
Number of Participants with An Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 52 weeks
Number of Participants Discontinuing From Study Therapy Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 52 weeks
Showing the first 100 of 161 sites across 24 countries. Choose a country and city above to see the rest.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Started Dec 2023 (actual). Primary completion is estimated for Jul 2027, 42 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bomedemstat